Criar um Site Grátis Fantástico

leukeran chlorambucil 2mg


Metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel when further anthracycline therapy is not indicated (eg, prior cumulative doses of 400mg/m2 of doxorubicin or its equivalents) leukeran chlorambucil 2mg. With docetaxel for metastatic breast cancer after failure of prior anthracycline-containing regimen. See full labeling. Give cyclically (2 weeks on, 1 week off). Swallow whole. Take with water within 30 minutes after AM & PM meals. leukeran chlorambucil 2mg?18yrs: 1250mg/m2 twice daily. Combination therapy: give with docetaxel 75mg/m2 IV infused over 1 hour every 3 weeks. Interrupt, adjust dose, and/or treat symptoms if toxicity occurs (eg, hyperbilirubinemia, diarrhea, nausea, vomiting, hand-and-foot syndrome, stomatitis) (see full labeling) do not increase dose afterwards. Renal impairment (CrCl 5180mL/min): monitor carefully (CrCl 3050mL/min): reduce capecitabine dose to 75% of starting dose (eg, 950mg/m2 twice daily). Hepatic or renal impairment. Monitor and correct dehydration at initiation. Coronary artery disease. Interrupt therapy if Grade 2/3 hand-and-foot syndrome, Grade 2/3 or 4 diarrhea occurs (give antidiarrheals) until resolves or reduces to Grade 1. Permanently discontinue if severe mucocutaneous reactions (eg, SJS, TEN) occur leukeran chlorambucil 2mg. Dihydropyrimidine dehydrogenase deficiency. Elderly. Embryo-fetal toxicity. Pregnancy: avoid exclude status prior to initiation. Females of reproductive potential should use effective contraception (during therapy and for 6 months) and males with female partners (during and for 3 months) after final dose. Nursing mothers: not recommended (during and for 2 weeks after final dose. Increased anticoagulant effect with warfarin monitor PT/INR frequently. Potentiated by leucovorin. Monitor phenytoin and other CYP2C9 substrates. Diarrhea, hand-and-foot syndrome, nausea, vomiting, abdominal pain, fatigue/weakness, hyperbilirubinemia lymphopenia, necrotizing enterocolitis, stomatitis, dermatitis, anorexia, cardiotoxicity, blood dyscrasias, paresthesias, eye irritation, edema, myalgia, dehydration, alopecia. Testing considerations: TS (thymidylate synthase), MSI (microsatellite instability), DPD (dihydropyrimidine dehydrogenase) First-line treatment of metastatic colorectal carcinoma when fluoropyrimidine therapy alone is preferred. Adjuvant treatment of Dukes' C colon cancer after complete resection of the primary tumor when fluoropyrimidine therapy alone is preferred. See full labeling. Give cyclically (2 weeks on, 1 week off). Swallow whole. Take with water within 30 minutes after AM & PM meals. ?18yrs: 1250mg/m2 twice daily. Continue for a total of 8 cycles. Interrupt, adjust dose, and/or treat symptoms if toxicity occurs (eg, hyperbilirubinemia, diarrhea, nausea, vomiting, hand-and-foot syndrome, stomatitis) (see full labeling) do not increase dose afterwards. Renal impairment (CrCl 5180mL/min): monitor carefully (CrCl 3050mL/min) leukeran chlorambucil 2mg: reduce capecitabine dose to 75% of starting dose (eg, 950mg/m2 twice daily). Hepatic or renal impairment. Monitor and correct dehydration at initiation. Coronary artery disease. Interrupt therapy if Grade 2/3 hand-and-foot syndrome, Grade 2/3 or 4 diarrhea occurs (give antidiarrheals) until resolves or reduces to Grade 1. Permanently discontinue if severe mucocutaneous reactions (eg, SJS, TEN) occur leukeran chlorambucil 2mg. Dihydropyrimidine dehydrogenase deficiency. Elderly. Embryo-fetal toxicity.

chlorambucil obinutuzumab
chlorambucil obinutuzumab cco
chlorambucil obinutuzumab protocol
chlorambucil ofatumumab cll
chlorambucil online
chlorambucil online pharmacy
chlorambucil oral
chlorambucil origin

Pregnancy: avoid exclude status prior to initiation. Females of reproductive potential should use effective contraception (during therapy and for 6 months) and males with female partners (during and for 3 months) after final dose. Nursing mothers: not recommended (during and for 2 weeks after final dose. Increased anticoagulant effect with warfarin monitor PT/INR frequently. Potentiated by leucovorin. Monitor phenytoin and other CYP2C9 substrates. Diarrhea, hand-and-foot syndrome, nausea, vomiting, abdominal pain, fatigue/weakness, hyperbilirubinemia lymphopenia, necrotizing enterocolitis, stomatitis, dermatitis, anorexia, cardiotoxicity, blood dyscrasias, paresthesias, eye irritation, edema, myalgia, dehydration, alopecia. Testing considerations: TS (thymidylate synthase), MSI (microsatellite instability) leukeran chlorambucil 2mg, DPD (dihydropyrimidine dehydrogenase) leukeran chlorambucil 2mg.

 
Criar um Site Grátis Incrível  -  Criar uma Loja online Grátis  -  Sites Grátis sem Limites  -  Criar uma Loja Virtual Grátis